Publications by authors named "Alison Church"

Claim this Profile
N
Nasal immunization with compound 48/80-adjuvanted acellular pertussis vaccines is an effective strategy to induce pertussis-specific systemic and mucosal immunity.
Alison Hofmann Church, Soman N Abraham, Herman F Staats, Brandi T Johnson-Weaver

Clin Exp Vaccine Res· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland.
Maheshi N Ramasamy, Elizabeth J Kelly, Seth Seegobin, Paul I Dargan, Ruth Payne, Alison Church

Lancet Microbe· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Umeclidinium/vilanterol as step-up therapy from tiotropium in patients with moderate COPD: a randomized, parallel-group, 12-week study.
Edward M Kerwin, Chris J Kalberg, Dmitry V Galkin, Chang-Qing Zhu, Alison Church

Int J Chron Obstruct Pulmon Dis· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, parallel-group study to evaluate the efficacy of umeclidinium/vilanterol 62.5/25 μg on health-related quality of life in patients with COPD.
Thomas M Siler, Alison C Donald, Dianne O'Dell, Alison Church, William A Fahy

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials.
John H Riley, Maggie Tabberer, Nathalie Richard, Alison Donald, Alison Church

Int J Chron Obstruct Pulmon Dis· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.
Gregory Feldman, François Maltais, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church

Int J Chron Obstruct Pulmon Dis· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mast cell desensitization inhibits calcium flux and aberrantly remodels actin.
W X Gladys Ang, Alison M Church, Mike Kulis, Hae Woong Choi, A Wesley Burks

J Clin Invest· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies.
Thomas M Siler, Edward Kerwin, Karen Singletary, Jean Brooks, Alison Church

COPD· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of umeclidinium added to inhaled corticosteroid/long-acting β2-agonist in patients with symptomatic COPD: a randomised, double-blind, parallel-group study.
Ana R Sousa, John H Riley, Alison Church, Chang-Qing Zhu, Yogesh S Punekar

NPJ Prim Care Respir Med· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic effects on treatment response of umeclidinium/vilanterol in chronic obstructive pulmonary disease.
Lynn Condreay, Lingkang Huang, Elizabeth Harris, Jean Brooks, John H Riley, Alison Church

Respir Med· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of once-daily inhaled umeclidinium/vilanterol in Asian patients with COPD: results from a randomized, placebo-controlled study.
Jinping Zheng, Nanshan Zhong, Amy Newlands, Alison Church, Aik H Goh

Int J Chron Obstruct Pulmon Dis· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomised, open-label study of umeclidinium glycopyrronium in patients with COPD.
Tara Rheault, Sanjeev Khindri, Mitra Vahdati-Bolouri, Alison Church, William A Fahy

ERJ Open Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses: Results from two randomised controlled trials.
James F Donohue, Dave Singh, Clara Munzu, Sally Kilbride, Alison Church

Respir Med· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies.
Thomas M Siler, Edward Kerwin, Ana R Sousa, Alison Donald, Rehan Ali, Alison Church

Respir Med· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Umeclidinium/vilanterol versus fluticasone propionate/salmeterol in COPD: a randomised trial.
Dave Singh, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church

BMC Pulm Med· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improvements in lung function with umeclidinium/vilanterol versus fluticasone propionate/salmeterol in patients with moderate-to-severe COPD and infrequent exacerbations.
James F Donohue, Sally Worsley, Chang-Qing Zhu, Liz Hardaker, Alison Church

Respir Med· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Daily variation in lung function in COPD patients with combined albuterol and ipratropium: results from a 4-week, randomized, crossover study.
Dave Singh, Chang-Qing Zhu, Sanjay Sharma, Alison Church, Chris J Kalberg

Pulm Pharmacol Ther· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of a combination of umeclidinium/vilanterol on exercise endurance in patients with chronic obstructive pulmonary disease: two randomized, double-blind clinical trials.
François Maltais, Sally Singh, Alison C Donald, Glenn Crater, Alison Church

Ther Adv Respir Dis· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trial.
M Reza Maleki-Yazdi, Thomas Kaelin, Nathalie Richard, Michael Zvarich, Alison Church

Respir Med· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of umeclidinium administered once or twice daily in patients with COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies.
James F Donohue, Christopher Kalberg, Palvi Shah, Misba Beerahee, Rashmi Mehta, Alison Church

J Clin Pharmacol· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics of inhaled umeclidinium and vilanterol in patients with chronic obstructive pulmonary disease.
Navin Goyal, Misba Beerahee, Chris Kalberg, Alison Church, Sally Kilbride

Clin Pharmacokinet· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study.
James F Donohue, Dennis Niewoehner, Jean Brooks, Dianne O'Dell, Alison Church

Respir Res· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Marc Decramer, Antonio Anzueto, Edward Kerwin, Thomas Kaelin, Nathalie Richard, Alison Church

Lancet Respir Med· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study.
Bartolome Celli, Glenn Crater, Sally Kilbride, Rashmi Mehta, Maggie Tabberer, Alison Church

Chest· May 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study.
Alison Church, Misba Beerahee, Jean Brooks, Rashmi Mehta, Palvi Shah

BMC Pulm Med· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis